CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. 2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19:1167–1214.
2.
CrouzeixG, MichelsJJ, SevinE, AideN, VaurD, BardetS. 2012. Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab, 97:3046–3050.
MarottaV, RamundoV, CameraL, PreteMD, FontiR, EspositoR, PalmieriG, SalvatoreM, VitaleM, ColaoA, FaggianoA. 2012. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety, exploratory analysis of role of serum thyroglobulin, FDG-PET. Clin Endocrinol (Oxf), 2012Sep25[Epub ahead of print]10.1111/cen.12057.
5.
FerraraN. 2002. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer, 2:795–803.
6.
TuttleRM, FleisherM, FrancisGL, RobbinsRJ. 2002. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab, 87:1737–1742.
7.
BauerAJ, TerrellR, DoniparthiNK, PatelA, TuttleRM, SajiM, RingelMD, FrancisGL. 2002. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid, 12:953–961.
8.
ShaikS, NuceraC, InuzukaH, GaoD, GarnaasM, FrechetteG, HarrisL, WanL, FukushimaH, HusainA, NoseV, FaddaG, SadowPM, GoesslingW, NorthT, LawlerJ, WeiW. 2012. SCF(beta-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med, 209:1289–1307.
CalipelA, LefevreG, PouponnotC, MouriauxF, EycheneA, MascarelliF. 2003. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem, 278:42409–42418.
11.
OuyangB, KnaufJA, SmithEP, ZhangL, RamseyT, YusuffN, BattD, FaginJA. 2006. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res, 12:1785–1793.
12.
NuceraC, NehsMA, NagarkattiSS, SadowPM, MekelM, FischerAH, LinPS, BollagGE, LawlerJ, HodinRA, ParangiS. 2011. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist, 16:296–309.
13.
UngerK, ZitzelsbergerH, SalvatoreG, SantoroM, BogdanovaT, BraselmannH, KastnerP, ZurnadzhyL, TronkoN, HutzlerP, ThomasG. 2004. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab, 89:4272–4279.
GuerraA, SapioMR, MarottaV, CampanileE, MorettiMI, DeandreaM, MottaM, LimonePP, FenziG, RossiG, VitaleM. 2011. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J, 58:31–38.
16.
VitaleM. 2012. Rethinking the role of oncogenes in papillary thyroid cancer initiation. Front Endocrinol (Lausanne), 3:83.
17.
GuerraA, SapioMR, MarottaV, CampanileE, RossiS, FornoI, FugazzolaL, BudillonA, MocciaT, FenziG, VitaleM. 2012. The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab, 97:517–524.
18.
GuerraA, FugazzolaL, MarottaV, CirilloM, RossiS, CirelloV, FornoI, MocciaT, BudillonA, VitaleM. 2012. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab, 97:2333–2340.
19.
VaskoV, HuS, WuG, XingJC, LarinA, SavchenkoV, TrinkB, XingM. 2005. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab, 90:5265–5269.
20.
CostaAM, HerreroA, FresnoMF, HeymannJ, AlvarezJA, Cameselle-TeijeiroJ, Garcia-RostanG. 2008. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf), 68:618–634.
21.
SancisiV, NicoliD, RagazziM, PianaS, CiarrocchiA. 2012. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab, 97:E1745–1749.
22.
JovanovicL, DelahuntB, McIverB, EberhardtNL, GrebeSK. 2008. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol, 215:145–154.
23.
XingM. 2012. BRAFV600E mutation and papillary thyroid cancer: chicken or egg?J Clin Endocrinol Metab, 97:2295–2298.
